Among them, pembrolizumab, an anti–PD-1 monoclonal antibody, has established itself as a key therapeutic tool in non–small cell lung cancer, melanoma, head and neck squamous cell carcinoma, and renal cell carcinoma, both in advanced disease and in high-risk early stages. The gene discussed is PDCD1; the disease is hereditary clear cell renal cell carcinoma.